Table 5 . Patients pre-transplant characteristics and outcomes of the haploidentical tranplants.
Pts Age/
sexe
Diagnostic and Pretranspl
status
Post transpl
status NK GvH
GVHD Ac. – Chron.
Proph.
DLI Day 45 *
GF D
F S
OS Cause of Death
CD34 106/kg
CD3 104/kg
STUDY 1: G + PROPHYLACTIC DLI
1 33/M AML M5, Rel2 refractory
CR + II
afer DLI
Lim. Yes 3X104
G 30 30 Infect/
GVHD in CR
1.8 1.83
2 27/M sAML
Primary refractory
CR - III
ater DLI
Ext. Yes 3X104
G 12 12 GVHD
In CR
3.0 0.68
3 47/F HD 3rd RR CR - I NE Yes G 03 03 Rel. 1.9 6.55
4 20/M ALL, CR (MRD +)
CR + No Lim. Yes G 108 108 CR 5.4 1.62
5 18/M ALL, Ph+
RR1
CR + No No Yes G 08 11 Rel. 3.4 1.52
6 40/F AUL,
Primary refractory
CR + No No Yes G 06 14 Rel. 2.6 1.72
7 30/M AML 1st Rel.
Partial remission
CR + No No Yes G 03 05 Rel. 3.6 2.82
8 32/M AML2 refr CR + No NE Yes G 02 03 Rel. 3.0 11.2
9 25/F ALL RR1 CR - III
Aft er 1st DLI
No Yes G 24 24 Rel. 1.7 21.6
Study 2: GM + 1 SINGLE PROPHYLACTIC DLI
10 43/M AML5 PR2 CR + II Lim. Yes GM 12 12 Rel. 5.5 1.19
11 54/M sAML PR1 CR + III Ext. Yes GM 24 24 GVHD
in CR
3.2 3.31
12 34/M CML AP2 CR + III Ext. Yes GM 05 05 GVHD
Infect.
in CR
2.3 4.61
13 56/F AML 2 PR3
CR - NE NE Yes GM 03 03 Infect. 5.2 3.13
14 56/F AML5, CR2 NE + NE NE Yes GM 02 02 Infect
/GVHD
7 10.25
15 50/M CML, CP2 CR - II Lim. Yes GM 86 86 CR 7.0 2.23
16 52/M AREB, PR2 CR - - - Yes GM 12 13 Infect
in CR
4.2 2.84
17 24/M AML4 PR1 CR + III Ext. Yes GM 09 09 GVHD
in CR
2.4 4.9 18 43/M Mantle NHL
RR
CR + III NE Yes GM 03 03 GVHD/
Infect in CR
2.5 1.78
19 34/M AML4, CR3 CR - II NE Yes GM 03 03 Cerebr
Hemorh
2.5 13.5 20 57/M NHL Prog
Rel.
NE - NE NE Yes GM 01 02 Progress
disease
4.8 9.44
21 F/36 AML4, CR2
CR - II Lim. Yes GM 74 74 En CR 2.2 0.71
Study 3: GM IF NO POTENTIAL NK GvH EFFECT
22 38/M ALL Refractory
Rel.
CR - III NE No GM 02 02 PTLD,
Infect.
MOF in CR
1.59 0.55
23 55/M AML2, CR2 NE + NE NE No No 0 0 Infect.
MOF in CR
1.4 1.12
24 26/M aplasia CR - - Lim. No No 12 12 CMV
Infect
3.4 5.47 25 23/M AML1
Refractory
CR - III Ext. No GM 08 08 GVHD/
Fungal Infect.
in CR
2.2 0.91
26 43/M CML AP3 CR + II Lim. No No 62 62 In CR 4.4 2.28
27 46/M CML, CP2 CR + II Ext. No No 09 09 GVHD,
Asperg.
MOF in CR
3.4 0.34
28 42/M sAML RR CR - III NE No GM 03 03 GVHD,
MOF in CR
1.9 11.29
29 36/M CML AP2 NE - NE NE No GM 01 01 Aspergil
losis Progress
disease
6.4 5.8
30 F/43 Ph+ ALL, secondary to
HD, CR2
CR + - - No GM 05 05 Cardiac
Arrythm ia in CR
7.0 4.44
31 44/M AML5 RefractoryR
el.
Post RIC Transplant
CR + II Lim. No No 10 10 Rel. 3.9 3.20
32 M/41 AML5, CR2
CR - II - No GM 54 54 En CR 4.3 7.06
33 23/M ALL
Refractory
CR - III - No GM 06 06 GVHD
Fungal infectio n in CR
1.8 2.90
34 35/F AML2 Rel.
after RIC transplant
PR2
CR + NE NE No No 01 01 Fungal
and viral infect in
CR
2.9 2.98
35 27/M CML AP1 CR + - - No No 04 04 VOD
Fungal infect ARDS in CR
4.4 0.21
36 21/M ALL CR2 CR - IV Ext. No GM 05 05 GVHD
Hepatic failure in CR
5 2.40
37 28/M CML, CP2 CR - - - Yes GM 36 36 CR
(DLI for MRD)
6.8 2.80
38 35/M CML, AP2 CR - III Ext. No Yes 14 14 GVHD, Infect.
in CR
4.8 3.90
39 36/F AML 2, Refractory
to 1st induction
CR1
CR + III Ext. No No 08 08 GVHD,
Fungal infect.
Micro- angiopat
in CR
8.2 16.71
40 53/M AML4, CR3 CR + III Ext. No Yes 10 10 GVHD,
Fungal Infect.
7.4 7.50
41 27/M AML1 Rel PR
CR + II NA No No 03 03 Rel. 4.2 4.23
42 25/M AML1, CR1 CR - III
§
No Yes 06 06 Rel.
Asperg.
2.3 2.46 43 36/F LAL Ph+
CR2
CR + 0 0 No Yes 03 03 ARDS
Aperg.
Alveol Hémorh
13.9 3.49
44 37/M CML, CP2 CR - - - No No 13 13 CR 10.4 2.64
45 30/F sAML5, CR1
CR + II - No No 11 11 CR 7.3 2.87
* Prophylactic DLI: 1 x 105 CD3/kg unless otherwise stated
Patients still in CR at the last follow-up date are highlighted in bold.
RR stands for refractory relapse, Lim. Stands for Lim., Ext. stands for Extended, Asperg. stands for invasive aspergillosis, Rel. stands for relapse, Infect. stands for infection, G stands for G-CSF, GM stands for GM-CSF, GF stands for Growth Factor.
§: late acute GVHD
